IL5 and anti-neutrophil cytoplasmic antibody-associated vasculitis: Terminal complement inhibition for management of ANCA-associated vasculitis with avacopan (51) and blockade of interleukin-5 for treatment of eosinophilic granulomatosis with polyangiitis with mepolizumab illustrate this trend (52).